For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibrodysplasia ossificans progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Fibrodysplasia ossificans progressiva Understanding
Fibrodysplasia ossificans progressiva: Overview
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body's skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible. Patients with FOP have malformed big toes that are present at birth (congenital). Other skeletal malformations may occur. The abnormal episodic development of bone at multiple soft tissue sites frequently leads to stiffness in affected areas, limited movement, and eventual ankylosis (fusion) of affected joints (neck, back, shoulders, elbows, hips knees, wrists, ankles, jaw - often in that order).
"Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibrodysplasia ossificans progressiva pipeline landscape is provided which includes the disease overview and Fibrodysplasia ossificans progressiva treatment guidelines. The assessment part of the report embraces, in depth Fibrodysplasia ossificans progressiva commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibrodysplasia ossificans progressiva collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Fibrodysplasia ossificans progressiva R&D. The therapies under development are focused on novel approaches to treat/improve Fibrodysplasia ossificans progressiva.
Fibrodysplasia ossificans progressiva Emerging Drugs Chapters
This segment of the Fibrodysplasia ossificans progressiva report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibrodysplasia ossificans progressiva Emerging Drugs
- Palovarotene: Ipsen
Palovarotene is a RAR? agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder, was acquired by Ipsen through the acquisition in April 2019 of Clementia Pharmaceuticals.
- BLU-782: Blueprint Medicines
BLU-782 is an orally administered, potent and highly selective ALK2 inhibitor. It was designed specifically to target the underlying genetic driver of fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling and ultimately life-shortening genetic disease.
Further product details are provided in the report ..
Fibrodysplasia ossificans progressiva: Therapeutic Assessment
This segment of the report provides insights about the different Fibrodysplasia ossificans progressiva drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Fibrodysplasia ossificans progressiva
There are approx. 10+ key companies which are developing the therapies for Fibrodysplasia ossificans progressiva. The companies which have their Fibrodysplasia ossificans progressiva drug candidates in the most advanced stage, i.e. preregistrtion include, Ipsen.
- Phases
DelveInsight's report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Fibrodysplasia ossificans progressiva pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Fibrodysplasia ossificans progressiva: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibrodysplasia ossificans progressiva therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibrodysplasia ossificans progressiva drugs.
Fibrodysplasia ossificans progressiva Report Insights
- Fibrodysplasia ossificans progressiva Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Fibrodysplasia ossificans progressiva Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Fibrodysplasia ossificans progressiva drugs?
- How many Fibrodysplasia ossificans progressiva drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibrodysplasia ossificans progressiva?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fibrodysplasia ossificans progressiva therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fibrodysplasia ossificans progressiva and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Ipsen
- Blueprint Medicines
- Regeneron Pharmaceuticals
- Daiichi Sankyo, Inc.
- AstraZeneca
- Incyte Corporation
- Keros Therapeutics
- BioCryst Pharmaceuticals
Key Products
- Palovarotene
- BLU 782
- REGN2477
- DS-6016a
- AZD0530
- INCB 000928
- KER 047
- BCX 9250
- BCX 9499